| Primary outcome |
| • A composite of all-cause in-hospital death, and, measured within the first 12 h of infusion initiation, any of the following: ◯ Sustained hypotension (mean arterial pressure ≤55 mmHg) or sustained requirement of high dose vasopressors (norepinephrine >0.2 mcg/kg/min or norepinephrine 0.2 mcg/kg/min plus any additional agent) with any escalation in dose from time of randomization, for ≥60 min ◯ Lactate greater than 3.5 mmol/L at 6 h or thereafter ◯ Need for mechanical circulatory support device ◯ Atrial or ventricular arrhythmia leading to emergent electrical cardioversion ◯ Resuscitated cardiac arrest |
| Secondary outcomes |
| • All-cause in-hospital death • Renal failure requiring new initiation of renal replacement therapy • Need for cardiac transplant or mechanical circulatory support • Atrial or ventricular arrhythmia leading to emergent electrical cardioversion • Resuscitated cardiac arrest • Non-fatal myocardial infarction • Stroke |
| Secondary efficacy outcomes |
| • Need for and number of days requiring non-invasive or invasive mechanical ventilation after randomization • Acute kidney injury |
| Secondary safety outcomes |
| • Atrial or ventricular arrhythmias requiring initiation of pharmacological intervention (intravenous or oral anti-arrhythmic therapy) |
| Primary outcome |
| • A composite of all-cause in-hospital death, and, measured within the first 12 h of infusion initiation, any of the following: ◯ Sustained hypotension (mean arterial pressure ≤55 mmHg) or sustained requirement of high dose vasopressors (norepinephrine >0.2 mcg/kg/min or norepinephrine 0.2 mcg/kg/min plus any additional agent) with any escalation in dose from time of randomization, for ≥60 min ◯ Lactate greater than 3.5 mmol/L at 6 h or thereafter ◯ Need for mechanical circulatory support device ◯ Atrial or ventricular arrhythmia leading to emergent electrical cardioversion ◯ Resuscitated cardiac arrest |
| Secondary outcomes |
| • All-cause in-hospital death • Renal failure requiring new initiation of renal replacement therapy • Need for cardiac transplant or mechanical circulatory support • Atrial or ventricular arrhythmia leading to emergent electrical cardioversion • Resuscitated cardiac arrest • Non-fatal myocardial infarction • Stroke |
| Secondary efficacy outcomes |
| • Need for and number of days requiring non-invasive or invasive mechanical ventilation after randomization • Acute kidney injury |
| Secondary safety outcomes |
| • Atrial or ventricular arrhythmias requiring initiation of pharmacological intervention (intravenous or oral anti-arrhythmic therapy) |
| Primary outcome |
| • A composite of all-cause in-hospital death, and, measured within the first 12 h of infusion initiation, any of the following: ◯ Sustained hypotension (mean arterial pressure ≤55 mmHg) or sustained requirement of high dose vasopressors (norepinephrine >0.2 mcg/kg/min or norepinephrine 0.2 mcg/kg/min plus any additional agent) with any escalation in dose from time of randomization, for ≥60 min ◯ Lactate greater than 3.5 mmol/L at 6 h or thereafter ◯ Need for mechanical circulatory support device ◯ Atrial or ventricular arrhythmia leading to emergent electrical cardioversion ◯ Resuscitated cardiac arrest |
| Secondary outcomes |
| • All-cause in-hospital death • Renal failure requiring new initiation of renal replacement therapy • Need for cardiac transplant or mechanical circulatory support • Atrial or ventricular arrhythmia leading to emergent electrical cardioversion • Resuscitated cardiac arrest • Non-fatal myocardial infarction • Stroke |
| Secondary efficacy outcomes |
| • Need for and number of days requiring non-invasive or invasive mechanical ventilation after randomization • Acute kidney injury |
| Secondary safety outcomes |
| • Atrial or ventricular arrhythmias requiring initiation of pharmacological intervention (intravenous or oral anti-arrhythmic therapy) |
| Primary outcome |
| • A composite of all-cause in-hospital death, and, measured within the first 12 h of infusion initiation, any of the following: ◯ Sustained hypotension (mean arterial pressure ≤55 mmHg) or sustained requirement of high dose vasopressors (norepinephrine >0.2 mcg/kg/min or norepinephrine 0.2 mcg/kg/min plus any additional agent) with any escalation in dose from time of randomization, for ≥60 min ◯ Lactate greater than 3.5 mmol/L at 6 h or thereafter ◯ Need for mechanical circulatory support device ◯ Atrial or ventricular arrhythmia leading to emergent electrical cardioversion ◯ Resuscitated cardiac arrest |
| Secondary outcomes |
| • All-cause in-hospital death • Renal failure requiring new initiation of renal replacement therapy • Need for cardiac transplant or mechanical circulatory support • Atrial or ventricular arrhythmia leading to emergent electrical cardioversion • Resuscitated cardiac arrest • Non-fatal myocardial infarction • Stroke |
| Secondary efficacy outcomes |
| • Need for and number of days requiring non-invasive or invasive mechanical ventilation after randomization • Acute kidney injury |
| Secondary safety outcomes |
| • Atrial or ventricular arrhythmias requiring initiation of pharmacological intervention (intravenous or oral anti-arrhythmic therapy) |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
